Sobi receives positive CHMP opinion for Kineret(R) for treatment of rare disease CAPS STOCKHOLM, Sweden, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...

The Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program STOCKHOLM, Sweden, Sept. 13, 2013 (GLOBE NEWSWIRE) -- The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 26 April 2013 resolved - for the purpose of ensuring that the company can...

Sobi acquires full rights for Kineret(R) and additional clinical data for Kepivance(R) from Amgen STOCKHOLM, Sweden, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that they have acquired the full rights to develop and commercialize Kineret (anakinra)...